AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04339348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inert placebo cream will be applied on the cervix at the time of LNG-IUD insertion plus vaginal placebo tablet 3 hours before LNG-IUD insertion
Study NCT01519752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxiconazole Nitrate Cream 1%
Description: Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
Study NCT01519752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxiconazole Nitrate Cream 1% (Oxistat®)
Description: Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
Study NCT01519752 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo applied to affected area once a day for 28 days
Study NCT00085436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin,
Description: Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
Study NCT00085436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous tumor cell vaccine
Description: we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
Study NCT00085436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
Study NCT03090763 — intervention group
Intervention type: GENETIC
Intervention: PCR and sequencing
Description: Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Captopril
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Enalapril
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lisinopril
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ramipril
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Trandolapril
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bisoprolol
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carvedilol
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol succinate
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Candesartan
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Valsartan
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eplerenone
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Spironolactone
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Diuretics
Study NCT00391846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: HF treatment according to Swedish guidelines
Study NCT00391846 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood samples
Study NCT00391846 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: The Kansas City Cardiomyopathy Questionnaire (KCCQ)
Study NCT00646035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: paricalcitol capsules
Description: baseline iPTH/60
Study NCT02986412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CG428
Description: The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
Study NCT01039948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-299 + gefitinib
Description: AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
Study NCT01039948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
Study NCT02424318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: topiramate 25mg twice 1 week -> topiramate 50mg twice 7 weeks
Study NCT00908505 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: physiotherapy either by biphasic cuirass ventilator or physiotherapist
Study NCT02231983 — intervention group
Intervention type: GENETIC
Intervention: gene sequencing
Description: Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
Study NCT03262623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial nerve block
Description: A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
Study NCT03262623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
Study NCT03388281 — intervention group
Intervention type: OTHER
Intervention: No intervention, retrospective analysis only.
Description: No intervention, retrospective analysis only.
Study NCT01164865 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lenses
Description: Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
Study NCT06088407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: with Tranexamic acid
Description: Patients undergoing surgery for elbow fracture-dislocation randomized to be treated with tranexamic acid intravenous intraoperatively
Study NCT04585451 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ALGOS System
Description: A Quantitative Electroencephalography (QEEG) based pain biomarker assessment that scales with patient reported Numeric Rating Scale (NRS)
Study NCT01170702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
Study NCT03583229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis
Description: 4 x ECP treatments in 60 days.
Study NCT01180283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lodenafil carbonate
Description: Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
Study NCT03980639 — intervention group
Intervention type: DRUG
Intervention: patient treated with DMARD
Description: Case report of cancer overall
Study NCT01285635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-101
Description: Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
Study NCT00054548 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oblimersen sodium
Description: Given IV
Study NCT00054548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00054548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00054548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01285635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 on Cycle Day 1
Study NCT01285635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 on Cycle Day 1
Study NCT03610568 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Growing up GREAT! Intervention
Description: The Growing up GREAT! intervention is built around the socio-ecological model. For young adolescents, a suite of materials provides information and prompts discussion about puberty, gender equality, healthy relationships, violence, and other related themes during weekly club sessions. For parents, group sessions featuring six testimonial videos foster discussion around non-violent parenting, equal sharing of household tasks, and girls' education. Other materials for teachers, health workers, and community members complement the core toolkit materials.
Study NCT01586403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
Study NCT01586403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10\^6 TIL 1383I TCR transduced T cells per kg body weight.
Study NCT01586403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 3
Description: Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
Study NCT01586403 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose 4
Description: Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10\^7 TIL 1383I TCR transduced T cells per kg body weight.
Study NCT02622451 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teen Intervene
Description: Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
Study NCT02622451 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Everyday Parenting
Description: Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
Study NCT03182582 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement
Description: Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
Study NCT03182582 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scalpel/Curette Debridement
Description: Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
Study NCT00968760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Leukapheresis #1 - For Collecting T Cells~Leukapheresis #2 - For Collecting Stem Cells, month following #1~Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete.
Study NCT00968760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem cell infusion by vein over 30-45 minutes on Day 0
Study NCT00968760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD19-specific T Cell Infusion
Description: T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
Study NCT00968760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Group 2 or 4, IL-2 dose of 0.3 x 10\^6 U/m\^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
Study NCT00968760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: 300 mg/m\^2 IV over 1 hour on Day -6
Study NCT02383472 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MedX Health Console model 1100
Description: All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line
Study NCT02383472 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MedX Health Console model 1100-placebo
Description: The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
Study NCT00781378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: rt-PA 100 mg continuous intravenous infusion for 2 hours
Study NCT00781378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: rt-PA 50 mg continuous intravenous infusion for 2 hours
Study NCT02793687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEXIDOL® (ethylmethylhydroxypyridine succinate)
Study NCT02793687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01613716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Ozurdex .7 mg injected into the treated eye
Study NCT04739280 — intervention group
Intervention type: DEVICE
Intervention: CardioFlux Magnetocardiography
Description: Magnetocardiography
Study NCT02486835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough syrup for adults and children
Description: Dosage is 5 ml three times a day for 4 nights, 3 days
Study NCT03564574 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lipid Emulsion
Description: All patients in the 'Study group' received a single dose of 100 ml of 20 percent Lipid emulsion as an infusion over 1 hour along with routine treatment as per institution protocols. Atropine was administered to patients by doubling dose method, which comprised of administering atropine starting from 2mg and to double the dose and administer till complete atropinization. Following this an infusion of 10 percent of the atropinizing dose was given every hour. Patients were evaluated using a standardized clinical interview, physical examination, laboratory tests.
Study NCT02389244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily until progression or unacceptable toxicity For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily until progression or unacceptable toxicity
Study NCT02486835 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage is 5 ml three times a day for 4 nights, 3 days
Study NCT00968760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 200 mg/m\^2 IV over 3 hours every 12 hours on Days -5 to -2
Study NCT00968760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 200 mg/m\^2 by vein over 1 hour every 12 hours on Days -5 to -2.
Study NCT00968760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 IV over 30 minutes on Day -1
Study NCT02758522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Once-daily Insulin
Description: Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
Study NCT02389244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For adults patients and children with BSA ≥1.70 m² : 4 tablets once daily and switch to regorafenib after confirmed progression For children with BSA ≥1.30 and ≤1.69 m² : 3 tablets once daily and switch to regorafenib after confirmed progression
Study NCT02758522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twice-daily Insulin
Description: Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
Study NCT02758522 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triple-daily Insulin
Description: Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI \< 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.